



Pfizer's Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research

Wednesday, July 08, 2015 - 04:30am

New Collaboration Aligns with Pfizer's Commitment to Immunology and Rare Disease Drug Discovery

"Accelerating drug discovery is the goal of every CTI collaboration and this agreement aligns with two of our core therapeutic areas, immunology and rare diseases, where we have leading expertise and a long history in research and bringing treatments to patients"

Pfizer's Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced today a collaboration agreement to conduct research in the field of immunological diseases. CTI and JMF will identify and co-fund translational research projects with leading academic medical centers within the CTI network. The goal of each research project will be to identify and validate a potential drug candidate for an immunological disease that can be moved into further clinical testing.

"Accelerating drug discovery is the goal of every CTI collaboration and this agreement aligns with two of our core therapeutic areas, immunology and rare diseases, where we have leading expertise and a long history in research and bringing treatments to patients," said Anthony J. Coyle, senior vice president and CTI's chief scientific officer. "With a deeply committed partner like the Jeffrey Modell Foundation, we have an opportunity to leverage our respective expertise to help enhance our understanding of

the complex immune system, which plays a key role in many rare diseases.”

The collaboration with CTI represents JMF’s first alliance with a biopharmaceutical company. “We are excited about the opportunity to collaborate with Pfizer as we broaden our commitment to make a world of difference in the lives of patients with immunological diseases,” said Vicki Modell, co-founder of the Jeffrey Modell Foundation. “JMF’s expertise in Primary Immunodeficiency and extensive network of collaborators, combined with Pfizer’s impressive research and development capabilities has the potential to identify and advance novel research projects. Together, we hope to make meaningful advancements in our understanding of immunological diseases.”

About Jeffrey Modell Foundation

Vicki and Fred Modell established the Jeffrey Modell Foundation in 1987, in memory of their son Jeffrey, who died at the age of fifteen from complications of Primary Immunodeficiency, a genetic condition that is chronic, serious, and often fatal.

JMF is a global non-profit organization dedicated to early diagnosis, meaningful treatments, and ultimately cures through research, physician education, public awareness, advocacy, patient support, and newborn screening. The Jeffrey Modell Centers Network (JMCN) includes 600 physicians at 248 academic institutions, in 206 cities in 79 countries, and spanning 6 continents, and growing.

For more information, visit www.info4pi.org or email the Jeffrey Modell Foundation at info4pi@jmfworld.org.

About Pfizer’s Center for Therapeutic Innovation

Launched in 2010, Pfizer’s Centers for Therapeutic Innovation (CTI) is a unique model for academic-foundation-industry collaborations, and to bridge the gap between early scientific discovery and its translation into potential new medicines. A key aspect of CTI is its local centers in biomedical research hubs that enable Pfizer and academic teams to work side-by-side, blending the academic institution’s expertise in disease biology, targets, and patient populations with Pfizer’s development expertise and resources. The ultimate goal of each collaborative research project is to identify a potential drug candidate that could be moved into further clinical testing. CTI now has 25 academic institutions and six foundations in its network, as well as the National Institutes of Health, with a portfolio of projects across a variety of disease areas. For more information, please visit www.PfizerCTI.com.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of July 8, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about research and development that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including, without limitation, the ability to meet anticipated clinical trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; whether and when any new drug applications may be filed with any jurisdiction for any of the product candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of our products and product candidates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available

at www.sec.gov and www.pfizer.com.

Pfizer Inc. Dean Mastrojohn, 212-733-6944 or Jeffrey Modell Foundation Vicki Modell, 212-819-0200 or Fred Modell, 212-819-0200